Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

25 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Isoniazid Articles

Rifampicine improves compliance says trial

20 October 2008

First commercial launch from Akorn Strides

21 July 2008

Glenmark acquires Bouwer Bartlett, and is at forefront of India

16 January 2006

Sandoz plans to sell generic drugs to Spain's hospitals

11 April 2005

WHO/Novartis TB drug deal; other firms urged

5 January 2004

People with HIV need free TB drugs: WHO

28 July 2003

FDA Clears HMR's Priftin, First TB Drug In 25 Years

25 June 1998

Successful TOBI Launch Boosts PathoGenesis

28 May 1998

PathoGenesis Drug Shows Activity vs TB

14 October 1996

Mycobutin Enters TB Prophylaxis Trials

27 February 1995

Rifater Marketed In USA

14 November 1994

Mixed Results From US Companies In 2nd Qtr

8 August 1994

MMD RECEIVES FDA OK FOR RIFATER

13 June 1994

US NDA FILED FOR RIFATER

12 July 1993

BARR LABS REINTRODUCES TWO DRUGS

28 June 1993

MYCOBUTIN PROMOTION DEAL

17 May 1993

B-MS RECEIVES APPROVAL FOR NYDRAZID

1 March 1993

DURAMED'S ISONIAZID

6 April 1992

DURAMED'S ISONIAZID

6 April 1992

Showing 1-19 of 19 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS